05:54 AM EST, 11/10/2025 (MT Newswires) -- Merck ( MRK ) said Sunday that a phase 3 study of its elicitide decanoate product candidate achieved its primary endpoint, demonstrating "statistically significant" reduction in low-density lipoprotein cholesterol, or LDL-C, in adult patients with heterozygous familial hypercholesterolemia.

The company said enlicitide led to a clinically meaningful LDL-C reduction of 59.4% compared with placebo at week 24. Enlicitide also demonstrated significant reductions in secondary endpoints such as non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) at week 24, Merck ( MRK ).

Merck ( MRK ) also said the product candidate's safety profile was comparable with placebo.